Windtree Therapeutics Debt-to-Equity Ratio Growth & History (WINT)
Windtree Therapeutics's debt-to-equity ratio was 0.12 for fiscal 2024.
View full Windtree Therapeutics company overviewWindtree Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 0.12 | −0.35 | −75.34% |
| 2023 | 2023-12-31 | 0.47 | 0.27 | +132.50% |
| 2022 | 2022-12-31 | 0.20 | 0.14 | +226.41% |
| 2021 | 2021-12-31 | 0.06 | 0.05 | +329.04% |
| 2020 | 2020-12-31 | 0.01 | −0.01 | −29.80% |
| 2019 | 2019-12-31 | 0.02 | −0.10 | −82.40% |
| 2018 | 2018-12-31 | 0.12 | — | — |
| 2015 | 2015-12-31 | 3.02 | 1.96 | +185.14% |
| 2014 | 2014-12-31 | 1.06 | 1.06 | +43597.79% |
| 2013 | 2013-12-31 | 0.00 | −0.01 | −80.25% |
| 2012 | 2012-12-31 | 0.01 | −0.22 | −94.68% |
| 2011 | 2011-12-31 | 0.23 | 0.18 | +362.49% |
| 2010 | 2010-12-31 | 0.05 | — | — |
Windtree Therapeutics quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | 2.41 | 2.02 | +515.27% |
| Q1 2025 | 2025-03-31 | 0.10 | 0.00 | +4.82% |
| Q4 2024 | 2024-12-31 | 0.12 | −0.35 | −75.34% |
| Q3 2024 | 2024-09-30 | 0.28 | 0.06 | +25.75% |
| Q2 2024 | 2024-06-30 | 0.39 | 0.24 | +153.15% |
| Q1 2024 | 2024-03-31 | 0.10 | −0.17 | −64.42% |
| Q4 2023 | 2023-12-31 | 0.47 | 0.27 | +132.50% |
| Q3 2023 | 2023-09-30 | 0.23 | 0.10 | +83.13% |
| Q2 2023 | 2023-06-30 | 0.15 | 0.04 | +30.83% |
| Q1 2023 | 2023-03-31 | 0.27 | 0.20 | +288.76% |
| Q4 2022 | 2022-12-31 | 0.20 | 0.14 | +226.41% |
| Q3 2022 | 2022-09-30 | 0.12 | 0.07 | +150.10% |
| Q2 2022 | 2022-06-30 | 0.12 | 0.07 | +153.02% |
| Q1 2022 | 2022-03-31 | 0.07 | 0.04 | +124.90% |
| Q4 2021 | 2021-12-31 | 0.06 | 0.05 | +329.04% |
| Q3 2021 | 2021-09-30 | 0.05 | 0.04 | +287.70% |
| Q2 2021 | 2021-06-30 | 0.05 | 0.03 | +237.26% |
| Q1 2021 | 2021-03-31 | 0.03 | 0.01 | +60.13% |
| Q4 2020 | 2020-12-31 | 0.01 | −0.01 | −29.80% |
| Q3 2020 | 2020-09-30 | 0.01 | −0.17 | −92.91% |
| Q2 2020 | 2020-06-30 | 0.01 | −0.15 | −91.73% |
| Q1 2020 | 2020-03-31 | 0.02 | −0.13 | −87.12% |
| Q4 2019 | 2019-12-31 | 0.02 | −0.10 | −82.40% |
| Q3 2019 | 2019-09-30 | 0.18 | — | — |
| Q2 2019 | 2019-06-30 | 0.17 | — | — |
| Q1 2019 | 2019-03-31 | 0.15 | — | — |
| Q4 2018 | 2018-12-31 | 0.12 | — | — |
| Q4 2015 | 2015-12-31 | 3.02 | 1.96 | +185.14% |
| Q3 2015 | 2015-09-30 | 1.40 | 0.71 | +103.97% |
| Q1 2015 | 2015-03-31 | 2.68 | 2.29 | +592.06% |
| Q4 2014 | 2014-12-31 | 1.06 | 1.06 | +43597.79% |
| Q3 2014 | 2014-09-30 | 0.69 | −0.48 | −41.37% |
| Q2 2014 | 2014-06-30 | 0.49 | 0.12 | +32.25% |
| Q1 2014 | 2014-03-31 | 0.39 | −0.26 | −40.59% |
| Q4 2013 | 2013-12-31 | 0.00 | −0.01 | −80.25% |
| Q3 2013 | 2013-09-30 | 1.17 | 1.16 | +16029.96% |
| Q2 2013 | 2013-06-30 | 0.37 | 0.37 | +7058.97% |
| Q1 2013 | 2013-03-31 | 0.65 | 0.65 | +13303.91% |
| Q4 2012 | 2012-12-31 | 0.01 | −0.22 | −94.68% |
| Q3 2012 | 2012-09-30 | 0.01 | −0.04 | −85.85% |
| Q2 2012 | 2012-06-30 | 0.01 | −0.02 | −81.55% |
| Q1 2012 | 2012-03-31 | 0.00 | — | — |
| Q4 2011 | 2011-12-31 | 0.23 | 0.18 | +362.49% |
| Q3 2011 | 2011-09-30 | 0.05 | — | — |
| Q2 2011 | 2011-06-30 | 0.03 | — | — |
| Q4 2010 | 2010-12-31 | 0.05 | — | — |
Windtree Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Windtree Therapeutics's debt-to-equity ratio increased from 0.02 to 0.12, a change of 0.10. The latest reported quarter, Q2 2025, shows 2.41.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Windtree Therapeutics source filings ↗